Gilead engaged Milliman to study changes in pricing of protected class drugs in recent years relative to other classes. For purposes of this report, cost trend is the annual percentage change in Wholesale Acquisition Cost per unit for highly utilized products in 2018 in Medicare Part D.
This report was commissioned by Gilead Sciences, Inc.